Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers

Despite its use for decades, pharmacokinetic (PK) and safety studies on colistin are limited. We conducted a phase l, open-label trial to evaluate the safety and PK of multiple doses of intravenous (IV) and aerosolized colistimethate sodium (CMS) administered separately and in combination. In total,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yendewa, George A., Griffiss, John McLeod, Gray, Wesley A., Healen, Amanda, Proskin, Howard M., Fulton, Scott A., O’Riordan, Mary Ann, Hoppel, Charles, Blumer, Jeffrey L., Salata, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029538/
https://www.ncbi.nlm.nih.gov/pubmed/35453240
http://dx.doi.org/10.3390/antibiotics11040490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029538/
https://www.ncbi.nlm.nih.gov/pubmed/35453240
http://dx.doi.org/10.3390/antibiotics11040490

Ejemplares similares